Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics DOI Creative Commons
Daniel Ejim Uti, Esther Ugo Alum, Item Justin Atangwho

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: May 7, 2025

Obesity is a major global health challenge, contributing to metabolic disorders such as type 2 diabetes, cardiovascular diseases, and hypertension. The increasing prevalence of obesity, driven by sedentary lifestyles, poor dietary habits, genetic predisposition, underscores the urgent need for effective therapeutic strategies. Conventional pharmacological treatments, including appetite suppressants modulators, often fail provide sustainable weight loss due side effects, adherence, limited long-term efficacy. As result, natural bioactive compounds have gained attention their anti-obesity potential. However, clinical application hindered bioavailability, rapid metabolism, inefficient delivery. Lipid-based nano-carriers, liposomes, solid lipid nanoparticles, nanostructured carriers, offer promising solution enhancing solubility, stability, targeted delivery these compounds. These advanced systems improve retention, enable controlled release, enhance action on adipose tissue pathways. Additionally, functionalized stimulus-responsive nanocarriers present innovative approaches precision obesity treatment. Despite advancements, challenges remain in large-scale production, regulatory approval, safety. Overcoming barriers critical ensuring successful translation nano-formulated therapies. This review explores potential lipid-based nano-carriers optimizing efficacy highlights role advancing next-generation management

Language: Английский

Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics DOI Creative Commons
Daniel Ejim Uti, Esther Ugo Alum, Item Justin Atangwho

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: May 7, 2025

Obesity is a major global health challenge, contributing to metabolic disorders such as type 2 diabetes, cardiovascular diseases, and hypertension. The increasing prevalence of obesity, driven by sedentary lifestyles, poor dietary habits, genetic predisposition, underscores the urgent need for effective therapeutic strategies. Conventional pharmacological treatments, including appetite suppressants modulators, often fail provide sustainable weight loss due side effects, adherence, limited long-term efficacy. As result, natural bioactive compounds have gained attention their anti-obesity potential. However, clinical application hindered bioavailability, rapid metabolism, inefficient delivery. Lipid-based nano-carriers, liposomes, solid lipid nanoparticles, nanostructured carriers, offer promising solution enhancing solubility, stability, targeted delivery these compounds. These advanced systems improve retention, enable controlled release, enhance action on adipose tissue pathways. Additionally, functionalized stimulus-responsive nanocarriers present innovative approaches precision obesity treatment. Despite advancements, challenges remain in large-scale production, regulatory approval, safety. Overcoming barriers critical ensuring successful translation nano-formulated therapies. This review explores potential lipid-based nano-carriers optimizing efficacy highlights role advancing next-generation management

Language: Английский

Citations

0